{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:18:17Z","timestamp":1789823897924,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00428-022-03465-7","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T12:06:07Z","timestamp":1670241967000},"page":"69-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Advances in myelodysplastic\/myeloproliferative neoplasms"],"prefix":"10.1007","volume":"482","author":[{"given":"Sonam","family":"Prakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-7013","authenticated-orcid":false,"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"3465_CR1","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/leu.2008.119","volume":"22","author":"A Orazi","year":"2008","unstructured":"Orazi A, Germing U (2008) The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22:1308\u20131319. https:\/\/doi.org\/10.1038\/leu.2008.119","journal-title":"Leukemia"},{"key":"3465_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds) (2017) WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). IARC: Lyon"},{"key":"3465_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"3465_CR4","doi-asserted-by":"publisher","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood blood.2022015850. https:\/\/doi.org\/10.1182\/blood.2022015850","DOI":"10.1182\/blood.2022015850"},{"key":"3465_CR5","unstructured":"Orazi A, Bennett JM, Germing U et al (2017) Chronic myelomonocytic leukemia. In Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). IARC: Lyon, pp 82-86"},{"key":"3465_CR6","unstructured":"Orazi A, Bennett JM, Bain BJ, et al (2017) Atypical chronic myeloid leukemia, BCR-ABL1-negative. In Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). IARC: Lyon, pp 87-88"},{"key":"3465_CR7","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1182\/blood-2016-07-728766","volume":"128","author":"PL Greenberg","year":"2016","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2016) Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood 128:2096\u20132097. https:\/\/doi.org\/10.1182\/blood-2016-07-728766","journal-title":"Blood"},{"key":"3465_CR8","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","volume":"104","author":"P Valent","year":"2019","unstructured":"Valent P, Orazi A, Savona MR et al (2019) Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica 104:1935\u20131949. https:\/\/doi.org\/10.3324\/haematol.2019.222059","journal-title":"Haematologica"},{"key":"3465_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjh.12756","volume":"165","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, Parikh SA, Hanson CA, Tefferi A (2014) Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 165:273\u2013286. https:\/\/doi.org\/10.1111\/bjh.12756","journal-title":"Br J Haematol"},{"key":"3465_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ijlh.13145","volume":"42","author":"VFI Sangiorgio","year":"2020","unstructured":"Sangiorgio VFI, Arber DA, Orazi A (2020) How I investigate chronic myelomonocytic leukemia. Int J Lab Hematol 42:101\u2013108. https:\/\/doi.org\/10.1111\/ijlh.13145","journal-title":"Int J Lab Hematol"},{"key":"3465_CR11","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/modpathol.3800707","volume":"19","author":"A Orazi","year":"2006","unstructured":"Orazi A, Chiu R, O\u2019Malley DP et al (2006) Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol 19:1536\u20131545. https:\/\/doi.org\/10.1038\/modpathol.3800707","journal-title":"Mod Pathol"},{"key":"3465_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1097\/PAS.0000000000001765","volume":"45","author":"SG Katz","year":"2021","unstructured":"Katz SG, Edappallath S, Xu ML (2021) IRF8 is a reliable monoblast marker for acute monocytic leukemias. Am J Surg Pathol 45:1391\u20131398. https:\/\/doi.org\/10.1097\/PAS.0000000000001765","journal-title":"Am J Surg Pathol"},{"key":"3465_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ajh.23751","volume":"89","author":"G Tang","year":"2014","unstructured":"Tang G, Zhang L, Fu B et al (2014) Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 89:813\u2013818. https:\/\/doi.org\/10.1002\/ajh.23751","journal-title":"Am J Hematol"},{"key":"3465_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc.2017.40","volume":"17","author":"MWN Deininger","year":"2017","unstructured":"Deininger MWN, Tyner JW, Solary E (2017) Turning the tide in myelodysplastic\/myeloproliferative neoplasms. Nat Rev Cancer 17:425\u2013440. https:\/\/doi.org\/10.1038\/nrc.2017.40","journal-title":"Nat Rev Cancer"},{"key":"3465_CR15","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","volume":"120","author":"M Meggendorfer","year":"2012","unstructured":"Meggendorfer M, Roller A, Haferlach T et al (2012) SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120:3080\u20133088. https:\/\/doi.org\/10.1182\/blood-2012-01-404863","journal-title":"Blood"},{"key":"3465_CR16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E et al (2016) Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 128:1408\u20131417. https:\/\/doi.org\/10.1182\/blood-2016-05-714030","journal-title":"Blood"},{"key":"3465_CR17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2018-08-867333","volume":"133","author":"C Cargo","year":"2019","unstructured":"Cargo C, Cullen M, Taylor J et al (2019) The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood 133:1325\u20131334. https:\/\/doi.org\/10.1182\/blood-2018-08-867333","journal-title":"Blood"},{"key":"3465_CR18","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S et al (2020) Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood 136:1851\u20131862. https:\/\/doi.org\/10.1182\/blood.2019004229","journal-title":"Blood"},{"key":"3465_CR19","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L et al (2013) Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 121:3005\u20133015. https:\/\/doi.org\/10.1182\/blood-2012-08-452938","journal-title":"Blood"},{"key":"3465_CR20","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A et al (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:2428\u20132436. https:\/\/doi.org\/10.1200\/JCO.2012.47.3314","journal-title":"J Clin Oncol"},{"key":"3465_CR21","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, Itzykson R, Lasho TL et al (2014) ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 28:2206\u20132212. https:\/\/doi.org\/10.1038\/leu.2014.125","journal-title":"Leukemia"},{"key":"3465_CR22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","volume":"34","author":"G Coltro","year":"2020","unstructured":"Coltro G, Mangaonkar AA, Lasho TL et al (2020) Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia 34:1407\u20131421. https:\/\/doi.org\/10.1038\/s41375-019-0690-7","journal-title":"Leukemia"},{"key":"3465_CR23","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","volume":"30","author":"JT Geyer","year":"2017","unstructured":"Geyer JT, Tam W, Liu Y-C et al (2017) Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol 30:1213\u20131222. https:\/\/doi.org\/10.1038\/modpathol.2017.45","journal-title":"Mod Pathol"},{"key":"3465_CR24","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1182\/bloodadvances.2020002206","volume":"4","author":"X Calvo","year":"2020","unstructured":"Calvo X, Garcia-Gisbert N, Parraga I et al (2020) Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Adv 4:5285\u20135296. https:\/\/doi.org\/10.1182\/bloodadvances.2020002206","journal-title":"Blood Adv"},{"key":"3465_CR25","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","volume":"125","author":"D Selimoglu-Buet","year":"2015","unstructured":"Selimoglu-Buet D, Wagner-Ballon O, Saada V et al (2015) Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 125:3618\u20133626. https:\/\/doi.org\/10.1182\/blood-2015-01-620781","journal-title":"Blood"},{"key":"3465_CR26","doi-asserted-by":"publisher","first-page":"e584","DOI":"10.1038\/bcj.2017.66","volume":"7","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM, Timm MM, Vallapureddy R et al (2017) Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J 7:e584. https:\/\/doi.org\/10.1038\/bcj.2017.66","journal-title":"Blood Cancer J"},{"key":"3465_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000365877","volume":"133","author":"D Peker","year":"2015","unstructured":"Peker D, Padron E, Bennett JM et al (2015) A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol 133:249\u2013256. https:\/\/doi.org\/10.1159\/000365877","journal-title":"Acta Haematol"},{"key":"3465_CR28","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1080\/10428194.2016.1243681","volume":"58","author":"MF Zahid","year":"2017","unstructured":"Zahid MF, Barraco D, Lasho TL et al (2017) Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 58:1488\u20131493. https:\/\/doi.org\/10.1080\/10428194.2016.1243681","journal-title":"Leuk Lymphoma"},{"key":"3465_CR29","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1016\/j.beha.2019.101134","volume":"33","author":"E Solary","year":"2020","unstructured":"Solary E, Wagner-Ballon O, Selimoglu-Buet D (2020) Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime? Best Pract Res Clin Haematol 33:101134. https:\/\/doi.org\/10.1016\/j.beha.2019.101134","journal-title":"Best Pract Res Clin Haematol"},{"key":"3465_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajh.26455","volume":"97","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM, Tefferi A (2022) Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:352\u2013372. https:\/\/doi.org\/10.1002\/ajh.26455","journal-title":"Am J Hematol"},{"key":"3465_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2018.05.003","volume":"70","author":"B Xicoy","year":"2018","unstructured":"Xicoy B, Triguero A, Such E et al (2018) The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. Leuk Res 70:34\u201336. https:\/\/doi.org\/10.1016\/j.leukres.2018.05.003","journal-title":"Leuk Res"},{"key":"3465_CR32","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/bloodadvances.2018019224","volume":"2","author":"S Loghavi","year":"2018","unstructured":"Loghavi S, Sui D, Wei P et al (2018) Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2:1807\u20131816. https:\/\/doi.org\/10.1182\/bloodadvances.2018019224","journal-title":"Blood Adv"},{"key":"3465_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/ijlh.13212","volume":"42","author":"K Foucar","year":"2020","unstructured":"Foucar K, Hsi ED, Wang SA et al (2020) Concordance among hematopathologists in classifying blasts plus promonocytes: a bone marrow pathology group study. Int J Lab Hematol 42:418\u2013422. https:\/\/doi.org\/10.1111\/ijlh.13212","journal-title":"Int J Lab Hematol"},{"key":"3465_CR34","doi-asserted-by":"publisher","first-page":"E614","DOI":"10.1002\/ajh.24861","volume":"92","author":"R Vallapureddy","year":"2017","unstructured":"Vallapureddy R, Lasho TL, Hoversten K et al (2017) Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. Am J Hematol 92:E614\u2013E618. https:\/\/doi.org\/10.1002\/ajh.24861","journal-title":"Am J Hematol"},{"key":"3465_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/modpathol.2012.218","volume":"26","author":"EL Courville","year":"2013","unstructured":"Courville EL, Wu Y, Kourda J et al (2013) Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 26:751\u2013761. https:\/\/doi.org\/10.1038\/modpathol.2012.218","journal-title":"Mod Pathol"},{"key":"3465_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/modpathol.2012.165","volume":"26","author":"L Boiocchi","year":"2013","unstructured":"Boiocchi L, Espinal-Witter R, Geyer JT et al (2013) Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol 26:204\u2013212. https:\/\/doi.org\/10.1038\/modpathol.2012.165","journal-title":"Mod Pathol"},{"key":"3465_CR37","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","volume":"31","author":"MA Elliott","year":"2007","unstructured":"Elliott MA, Verstovsek S, Dingli D et al (2007) Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 31:1503\u20131509. https:\/\/doi.org\/10.1016\/j.leukres.2006.12.025","journal-title":"Leuk Res"},{"key":"3465_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","volume":"42","author":"HD Gur","year":"2018","unstructured":"Gur HD, Loghavi S, Garcia-Manero G et al (2018) Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p. V617F mutations. Am J Surg Pathol 42:799\u2013806. https:\/\/doi.org\/10.1097\/PAS.0000000000001058","journal-title":"Am J Surg Pathol"},{"key":"3465_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.humpath.2018.10.026","volume":"85","author":"Z Hu","year":"2019","unstructured":"Hu Z, Ramos CEB, Medeiros LJ et al (2019) Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis. Hum Pathol 85:290\u2013298. https:\/\/doi.org\/10.1016\/j.humpath.2018.10.026","journal-title":"Hum Pathol"},{"key":"3465_CR40","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/modpathol.2017.148","volume":"31","author":"J Chapman","year":"2018","unstructured":"Chapman J, Geyer JT, Khanlari M et al (2018) Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Mod Pathol 31:429\u2013441. https:\/\/doi.org\/10.1038\/modpathol.2017.148","journal-title":"Mod Pathol"},{"key":"3465_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajh.23373","volume":"88","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Lasho TL, Finke CM et al (2013) Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 88:201\u2013206. https:\/\/doi.org\/10.1002\/ajh.23373","journal-title":"Am J Hematol"},{"key":"3465_CR42","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1182\/bloodadvances.2020003345","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Loghavi S, Mangaonkar AA et al (2020) SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv 4:5716\u20135721. https:\/\/doi.org\/10.1182\/bloodadvances.2020003345","journal-title":"Blood Adv"},{"key":"3465_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1182\/blood.2021011323","volume":"138","author":"A Gall\u00ec","year":"2021","unstructured":"Gall\u00ec A, Todisco G, Catamo E et al (2021) Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood 138:965\u2013976. https:\/\/doi.org\/10.1182\/blood.2021011323","journal-title":"Blood"},{"key":"3465_CR44","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","volume":"123","author":"SA Wang","year":"2014","unstructured":"Wang SA, Hasserjian RP, Fox PS et al (2014) Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms. Blood 123:2645\u20132651. https:\/\/doi.org\/10.1182\/blood-2014-02-553800","journal-title":"Blood"},{"key":"3465_CR45","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","volume":"102","author":"SA Wang","year":"2017","unstructured":"Wang SA, Hasserjian RP, Tam W et al (2017) Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica 102:1352\u20131360. https:\/\/doi.org\/10.3324\/haematol.2017.165340","journal-title":"Haematologica"},{"key":"3465_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","volume":"45","author":"R Piazza","year":"2013","unstructured":"Piazza R, Valletta S, Winkelmann N et al (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45:18\u201324. https:\/\/doi.org\/10.1038\/ng.2495","journal-title":"Nat Genet"},{"key":"3465_CR47","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/leu.2013.133","volume":"27","author":"M Meggendorfer","year":"2013","unstructured":"Meggendorfer M, Bacher U, Alpermann T et al (2013) SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 27:1852\u20131860. https:\/\/doi.org\/10.1038\/leu.2013.133","journal-title":"Leukemia"},{"key":"3465_CR48","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.leukres.2008.04.024","volume":"32","author":"F Fend","year":"2008","unstructured":"Fend F, Horn T, Koch I et al (2008) Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leuk Res 32:1931\u20131935. https:\/\/doi.org\/10.1016\/j.leukres.2008.04.024","journal-title":"Leuk Res"},{"key":"3465_CR49","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/2040620715607416","volume":"6","author":"S Giri","year":"2015","unstructured":"Giri S, Pathak R, Martin MG, Bhatt VR (2015) Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: a retrospective analysis of the surveillance, epidemiology and end results database. Ther Adv Hematol 6:308\u2013312. https:\/\/doi.org\/10.1177\/2040620715607416","journal-title":"Ther Adv Hematol"},{"key":"3465_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/fon-2017-0334","volume":"14","author":"P Dhakal","year":"2018","unstructured":"Dhakal P, Gundabolu K, Amador C et al (2018) Atypical chronic myeloid leukemia: a rare entity with management challenges. Future Oncol 14:177\u2013185. https:\/\/doi.org\/10.2217\/fon-2017-0334","journal-title":"Future Oncol"},{"key":"3465_CR51","unstructured":"Orazi A, Hasserjian RP, Cazzola M et al (2017) Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. In Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). IARC: Lyon, pp 93-94"},{"key":"3465_CR52","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","volume":"114","author":"L Malcovati","year":"2009","unstructured":"Malcovati L, Della Porta MG, Pietra D et al (2009) Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 114:3538\u20133545. https:\/\/doi.org\/10.1182\/blood-2009-05-222331","journal-title":"Blood"},{"key":"3465_CR53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ajh.26090","volume":"96","author":"MM Patnaik","year":"2021","unstructured":"Patnaik MM, Tefferi A (2021) Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \u201c2021 update on diagnosis, risk-stratification, and management.\u201d Am J Hematol 96:379\u2013394. https:\/\/doi.org\/10.1002\/ajh.26090","journal-title":"Am J Hematol"},{"key":"3465_CR54","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/leu.2013.120","volume":"27","author":"J Bros\u00e9us","year":"2013","unstructured":"Bros\u00e9us J, Alpermann T, Wulfert M et al (2013) Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 27:1826\u20131831. https:\/\/doi.org\/10.1038\/leu.2013.120","journal-title":"Leukemia"},{"key":"3465_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E et al (2020) SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood 136:157\u2013170. https:\/\/doi.org\/10.1182\/blood.2020004850","journal-title":"Blood"},{"key":"3465_CR56","doi-asserted-by":"publisher","first-page":"E246","DOI":"10.1002\/ajh.26182","volume":"96","author":"G Montalban-Bravo","year":"2021","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F et al (2021) Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol 96:E246\u2013E249. https:\/\/doi.org\/10.1002\/ajh.26182","journal-title":"Am J Hematol"},{"key":"3465_CR57","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","volume":"100","author":"S Jeromin","year":"2015","unstructured":"Jeromin S, Haferlach T, Weissmann S et al (2015) Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica 100:e125\u2013e127. https:\/\/doi.org\/10.3324\/haematol.2014.119032","journal-title":"Haematologica"},{"key":"3465_CR58","unstructured":"Orazi A, Bennett JM, Bain BJ et al (2017) Myelodysplastic\/myeloproliferative neoplasm, unclassifiable. In Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). IARC: Lyon, pp 95-96"},{"key":"3465_CR59","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41379-021-00961-0","volume":"35","author":"R Kanagal-Shamanna","year":"2022","unstructured":"Kanagal-Shamanna R, Orazi A, Hasserjian RP et al (2022) Myelodysplastic\/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol 35:470\u2013479. https:\/\/doi.org\/10.1038\/s41379-021-00961-0","journal-title":"Mod Pathol"},{"key":"3465_CR60","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1002\/cncr.26537","volume":"118","author":"R Kanagal-Shamanna","year":"2012","unstructured":"Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B et al (2012) Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118:2879\u20132888. https:\/\/doi.org\/10.1002\/cncr.26537","journal-title":"Cancer"},{"key":"3465_CR61","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1365-2141.1999.01537.x","volume":"106","author":"RF McClure","year":"1999","unstructured":"McClure RF, Dewald GW, Hoyer JD, Hanson CA (1999) Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder\/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 106:445\u2013454. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01537.x","journal-title":"Br J Haematol"},{"key":"3465_CR62","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ajh.23755","volume":"89","author":"V Visconte","year":"2014","unstructured":"Visconte V, Tabarroki A, Zhang L et al (2014) Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). Am J Hematol 89:862. https:\/\/doi.org\/10.1002\/ajh.23755","journal-title":"Am J Hematol"},{"key":"3465_CR63","doi-asserted-by":"publisher","first-page":"14251","DOI":"10.18632\/oncotarget.7350","volume":"7","author":"R Kanagal-Shamanna","year":"2016","unstructured":"Kanagal-Shamanna R, Luthra R, Yin CC et al (2016) Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7:14251\u201314258. https:\/\/doi.org\/10.18632\/oncotarget.7350","journal-title":"Oncotarget"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03465-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:23:04Z","timestamp":1674847384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03465-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03465-7","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}